Throughout Thursday’s buying and selling session, the shares of an organization engaged in offering infrastructural providers surged practically 11.6 %, after the corporate introduced securing a piece order price Rs. 268.92 crores from Border Roads Group (BRO).
Worth Motion
With a market cap of Rs. 211.8 crores, the shares of Niraj Cement Structurals Restricted closed within the inexperienced at Rs. 49 on BSE, up by round 6.3 %, as in comparison with its earlier closing value of Rs. 46.1.
The inventory has delivered constructive returns of practically 28 % over one yr, whereas round 2 % of unfavorable returns in a single month.
What’s the information
As per the most recent regulatory filings, Niraj Cement Structurals Restricted introduced that the Niraj-Satish Joint Enterprise (JV) has secured a piece order for the development of a 4-lane Greenfield bypass (Pattan Bypass) with paved shoulders on the Srinagar-Baramulla-Uri (NH-01) route in Jammu and Kashmir.
The undertaking, awarded beneath Challenge Beacon by the Border Roads Group (BRO), spans from Current Ch. Km 24.320 to Km 33.760 (Design Ch. Km 24.400 to Km 35.300), masking a complete size of 10.9 km.
The contract, valued at Rs. 268.92 crore (excluding GST), can be executed in EPC mode and is anticipated to be accomplished inside 24 months.
Additionally learn: Mukul Agrawal inventory jumps after receiving $606,000 brass billets order from Dubai-based Co.
Financials
Niraj Cement reported a decline in income from operations, experiencing a year-on-year lower of practically 5.5 %, falling from Rs. 126.6 crores in Q3 FY24 to Rs. 119.7 crores in Q3 FY25.
Nevertheless, throughout the identical interval, the corporate’s web revenue elevated from Rs. 1.3 crore to Rs. 2.2 crore, indicating an increase of round 68 % YoY.
Concerning the firm
Niraj Cement Structurals Restricted is engaged within the enterprise of offering infrastructure and building providers for highways, expressways, turnkey tasks, roads, bridges, tunnels, and allied works.
Written by Shivani Singh
Disclaimer
The views and funding ideas expressed by funding consultants/broking homes/score companies on tradebrains.in are their very own, and never that of the web site or its administration. Investing in equities poses a danger of economic losses. Buyers should due to this fact train due warning whereas investing or buying and selling in shares. Dailyraven Applied sciences or the writer should not responsible for any losses precipitated because of the choice based mostly on this text. Please seek the advice of your funding advisor earlier than investing.
